CancerCompass is dedicated to provided you with the most up to date cancer information and news. Visit our website to find all our articles on General Cancer News http://www.cancercompass.com/cancer-news.htm Sat, 07 Nov 2009 00:00:00 GMT Sat, 07 Nov 2009 00:00:00 GMT http://backend.userland.com/rss RSS.NET: http://www.rssdotnet.com/ According to recent research from the United States, Bacterial infection is the most common complication of chemotherapy-induced neutropenia particularly in patients with hematologic malignancies. Bacterial infections predominate during the initial phases of neutropenic episodes. http://www.cancercompass.com/cancer-news/article/32379.htm CancerCompass Fri, 06 Nov 2009 00:00:00 GMT The Healthy Exercise for Lymphoma Patients (HELP) trial, a three-year study led by Kerry Courneya, Canada Research Chair in physical activity and cancer in the Faculty of Physical Education and Recreation, found that a regimen of aerobic exercise training produced significant improvements in physical functioning and overall quality of life benefits in patients with lymphoma. http://www.cancercompass.com/cancer-news/article/32378.htm CancerCompass Fri, 06 Nov 2009 00:00:00 GMT About 100,500 new cases of cancer are caused by obesity every year, according to the most comprehensive attempt ever to estimate the cancers attributed to extra weight. The analysis, released today by the American Institute for Cancer Research, is based on updated cancer data and a report released earlier this year by a panel of experts. Among the types of cancer most strongly linked to excess body fat: http://www.cancercompass.com/cancer-news/article/32377.htm CancerCompass Fri, 06 Nov 2009 00:00:00 GMT Despite a recent study finding that an increasing number of women who had cancer in one breast are opting to have the other breast removed, the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for Breast Cancer discourages prophylactic mastectomy in women except for those considered high risk. http://www.cancercompass.com/cancer-news/article/32375.htm CancerCompass Fri, 06 Nov 2009 00:00:00 GMT Gloucester Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) approved ISTODAX(R) (romidepsin) for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. http://www.cancercompass.com/cancer-news/article/32376.htm CancerCompass Fri, 06 Nov 2009 00:00:00 GMT Most biopsies following mammograms reveal benign abnormalities, not cancer. But women may not have to endure the medical costs, stress and potential complications that accompany such invasive biopsies forever. A University of Florida biomedical engineering researcher is making progress on an optical biopsy that has the potential to determine whether growths are cancerous without ever puncturing the skin. http://www.cancercompass.com/cancer-news/article/32374.htm CancerCompass Fri, 06 Nov 2009 00:00:00 GMT One of Australia's proudest scientific achievements of recent years, the vaccine against cervical cancer, may turn out to even more important than anyone Research published in the British Journal or" Cancer suggests that the vaccine may also prevent some breast cancers. http://www.cancercompass.com/cancer-news/article/32373.htm CancerCompass Fri, 06 Nov 2009 00:00:00 GMT A recently discovered form of the protein that triggers blood clotting may play a key role in the molecular mechanisms leading to the growth of certain metastatic cancers, according to new research reported by an international team of scientists. http://www.cancercompass.com/cancer-news/article/32371.htm CancerCompass Fri, 06 Nov 2009 00:00:00 GMT According to a study from the United States, Malignant gliomas are characterized by invasive and infiltrative behavior that generally involves the destruction of normal brain tissue. Strategies to treat infiltrating gliomas, such as chemotherapy and gene therapy, have remained largely unsuccessful. http://www.cancercompass.com/cancer-news/article/32372.htm CancerCompass Fri, 06 Nov 2009 00:00:00 GMT Polo-like kinase 1 (Plk1) is becoming an increasingly attractive target for cancer management. Plk1 has been shown to be overexpressed in a variety of cancers; however its role in skin cancers is not well-understood, scientists in the United States report. http://www.cancercompass.com/cancer-news/article/32370.htm CancerCompass Fri, 06 Nov 2009 00:00:00 GMT U.S. scientists say they have discovered a small molecule that inhibits the actions of a protein cancer cells require for survival. The researchers said they determined the molecule, called PES, inhibits a type of protein called a heat-shock protein that helps cells survive heat, lack of nutrients and other cell-damaging conditions. http://www.cancercompass.com/cancer-news/article/32368.htm CancerCompass Fri, 06 Nov 2009 00:00:00 GMT We sought to improve outcomes for patients with high-risk head and neck squamous cell cancer (HNSCC) after surgical resection by testing the feasibility and safety of early postoperative chemotherapy followed by concurrent chemoradiotherapy. Eligible patients had resected, stages III to IV HNSCC with positive margins, extracapsular nodal extension, or multiple positive nodes, investigators in the United States report. http://www.cancercompass.com/cancer-news/article/32369.htm CancerCompass Fri, 06 Nov 2009 00:00:00 GMT Drugs used to treat psychiatric disorders are highly effective at killing cancer cells, opening up potential new lines of treatments. Dr Louise Lurze-Mann of the University of NSW School of Biotechnology and Biomolecular Sciences was talking with psychiatric researchers at the University of Queensland when they mentioned that people with diseases like schizophrenia appear to have low rates of cancer, despite being more inclined to smoke than the general population. http://www.cancercompass.com/cancer-news/article/32367.htm CancerCompass Fri, 06 Nov 2009 00:00:00 GMT Mouth cancer (also called oral cancer) is a malignant growth which can occur in any part of the mouth including the lips and tongue. In the UK, the numbers of new cases have risen by over 41 per cent over the last ten years(1). About 5,325 people get cancer of the mouth each year and the disease kills one person every five hours. Treated in its early stages, mouth cancer is curable but if not detected early, it kills around one in two sufferers. http://www.cancercompass.com/cancer-news/article/32366.htm CancerCompass Fri, 06 Nov 2009 00:00:00 GMT It's a safe bet to presume there are soup recipes in today's column because it's colder, furnaces are running and it just seems like a fall thing to do. http://www.cancercompass.com/cancer-news/article/32365.htm CancerCompass Fri, 06 Nov 2009 00:00:00 GMT Results of two phase 1 studies demonstrate that the novel, investigational cancer vaccines MKC1106-MT and MKC1106-PP are well-tolerated and show encouraging immune response rates and objective tumor response in advanced melanoma, prostate cancer and other solid malignancies, setting the stage for phase 2 studies. The data are being presented at the International Society for Biological Therapy of Cancer 2009 Annual Meeting. http://www.cancercompass.com/cancer-news/article/32364.htm CancerCompass Fri, 06 Nov 2009 00:00:00 GMT Results of the FDA pivotal clinical trial for the LightTouch(TM) Non-invasive Cervical Cancer Detection Device conducted by Guided Therapeutics, Inc. (GT), indicated that the current system for diagnosing cervical disease missed the same amount of disease as a landmark study carried out by the National Cancer Institute (NCI). http://www.cancercompass.com/cancer-news/article/32362.htm CancerCompass Fri, 06 Nov 2009 00:00:00 GMT Researchers at Yale University have developed synthetic molecules capable of enhancing the body's immune response to HIV and HIV-infected cells, as well as to prostate cancer cells. Their findings, published online in the Journal of the American Chemical Society, could lead to novel therapeutic approaches for these diseases. http://www.cancercompass.com/cancer-news/article/32363.htm CancerCompass Fri, 06 Nov 2009 00:00:00 GMT Uterine serous carcinomas typically have a characteristic morphology (papillary architecture, high-grade nuclei) and immunoprofile (diffuse/strong p53 expression, loss of hormone receptor expression) that distinguish them from most endometrial endometrioid carcinomas. http://www.cancercompass.com/cancer-news/article/32361.htm CancerCompass Fri, 06 Nov 2009 00:00:00 GMT A Dutch study that included nearly 90,000 women finds that liquid-based cytology, a commonly used alternative to conventional Pap tests, is not superior to Pap tests for the detection of cervical cancer precursors or cancer, according to a study in the October 28 issue of JAMA. http://www.cancercompass.com/cancer-news/article/32359.htm CancerCompass Fri, 06 Nov 2009 00:00:00 GMT